Bayer powers gene-editing startup Metagenomi to $65M A round

Metagenomi has raised $65 million to apply its suite of CRISPR-based systems to the treatment of genetic diseases. Leaps by Bayer co-led the series A round, continuing the German conglomerate’s multi-front push into cell and gene therapies.